Ferring Laboratories

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group focused on reproductive medicine, maternal health, and specialty areas within gastroenterology and urology. Founded in 1950 and headquartered in Switzerland, the company is a pioneer in the development of peptide-based drugs and hormone therapies. Ferring has recently expanded its portfolio into innovative modalities, including the first FDA-approved fecal microbiota-based product, Rebyota, and the gene therapy Adstiladrin for bladder cancer. The company operates globally with a significant presence in over 50 countries and maintains a strong commitment to addressing unmet needs in women's health and gut health.